-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Allogene Therapeutics, Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from Q4 2017 to Q1 2024.
- Allogene Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $1.65M, a 4.68% decline year-over-year.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $117M, a 21.9% increase from 2023.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $95.7M, a 3144% increase from 2022.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $2.95M, a 75.3% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)